The two paths in plain language
In 2026, a new GLP-1 patient chooses between two dominant access paths. Each has predictable strengths and weaknesses.
Telehealth bundle. A subscription that bundles an asynchronous or live video visit with a licensed clinician, a prescription (usually compounded semaglutide or tirzepatide from a 503A pharmacy, sometimes branded via LillyDirect referral), shipping, and ongoing message-based support. Representative operators and 2026 pricing: Hims & Hers weight-loss program ($199–$349/mo), Ro Body Program ($145/mo subscription + drug), Henry Meds ($249–$399/mo bundled), Mochi Health ($79/mo subscription + drug, cash via marketplace), Found, Sequence (Weight Watchers Clinic), and smaller regional 503A-partnered practices.
In-person path. A primary-care physician, obesity-medicine specialist, or endocrinologist who performs a traditional new-patient visit, writes a prescription that goes through your retail or mail-order pharmacy, and sees you quarterly. Typical costs: new-patient visit $200–$350 cash (or $30–$75 copay insured), follow-ups $100–$200 cash or $20–$50 copay, drug filled at your pharmacy at insurance-negotiated or cash price. For insured patients with coverage, Wegovy or Zepbound copays are commonly $25–$100/month with manufacturer savings cards; without coverage, expect $499 via LillyDirect or NovoCare self-pay, $1,086–$1,349 at full list.
When telehealth wins on cost
Telehealth is almost always cheaper if you are uninsured or your commercial plan does not cover AOMs. The bundle absorbs the 503A compounded sema or tirzepatide at wholesale-tier pricing ($80–$140/month drug cost), then retails the bundle at $249–$399. Even at the high end, that beats $499 LillyDirect + $200 quarterly clinic visits.
Telehealth also beats in-person on time cost. No travel, no waiting room, no PTO for a 15-minute visit. For busy working adults, the implicit hourly value saved is real.
When the in-person clinic wins
Five scenarios where an in-person specialist is usually the better clinical and financial choice:
- You have commercial coverage for AOMs. Your $25–$100 copay on Wegovy or Zepbound beats any telehealth bundle. Prior auth work is handled by the clinic’s staff. Your prior auth likelihood is your biggest lever.
- You have type 2 diabetes or significant cardiometabolic disease. You need lab ordering, insulin dose coordination, and a longitudinal relationship. Telehealth can do labs but it is piecemeal; your endocrinologist can do it in one visit.
- You are over 65 on Medicare. Medicare Part D only covers GLP-1s for approved indications (T2D, cardiovascular risk reduction per SELECT). Getting the correct indication documented requires an in-person visit in nearly every state. Telehealth cannot reliably get Wegovy or Zepbound approved on Medicare.
- You have complex medication interactions or contraindications. Personal or family history of MTC/MEN2, prior pancreatitis, or brittle diabetes warrants an in-person eval.
- You need a multidisciplinary approach. Bariatric surgery candidacy, a registered dietitian, behavioral therapy — most insurance networks structure these as in-person referrals.
The quality dimension most cost comparisons skip
Telehealth GLP-1 programs vary enormously in clinical rigor. The good ones require labs at baseline and q6 months, screen for contraindications, slow titration when side effects appear, and have a live clinician available for clinical messaging. The less good ones issue a prescription based on a 3-question intake form and have a call center for questions.
Questions to ask before signing up for a telehealth program:
- Will a licensed clinician (MD, DO, NP, or PA) review my chart before prescribing?
- Does the program require baseline labs before starting, and follow-up labs q6 months?
- What is the policy for side-effect management — how fast can I reach a clinician?
- Which 503A pharmacy compounds my prescription? Can I see the COA?
- What happens if my dose needs to be held? Can the program pause the subscription?
- Is the prescription transferable if I switch to insurance coverage later?
Hybrid: the emerging winner for many patients
A pattern that has emerged in 2025–2026: use a telehealth platform for the drug and convenience, and maintain a primary-care or obesity-medicine relationship for labs, comorbidity management, and paper-trail continuity. The hybrid increases cost by $200–$400/year (2 PCP visits with labs) but preserves continuity of care and positions you for insurance coverage if you later qualify. If your PCP is in-network and takes your insurance, this hybrid is often the best value.
What the trials implicitly assume about care setting
STEP 1, STEP 2, STEP 3 (with intensive behavioral therapy), SURMOUNT-1, and SELECT all enrolled patients through academic medical centers or large multi-site clinical networks. Visits were quarterly or more frequent with a trained obesity-medicine or endocrinology investigator. Labs were drawn at baseline, week 12, week 24, week 52, and week 68/72. Side effects were managed proactively. When you read “14.9% mean TBWL on semaglutide” or “22.5% on tirzepatide 15 mg,” that efficacy was achieved with high-touch care. Real-world outcomes on both telehealth and in-person paths trail trial means for predictable reasons: adherence gaps, dose-escalation interruptions from side effects, discontinuation. A 2024 Blue Cross analysis found <25% of commercial Wegovy/Zepbound starters remained on therapy at 12 months. Programs that replicate the trial setting — quarterly labs, proactive side-effect outreach, continuity of clinician — produce real-world TBWL closer to trial means. Bare-bones telehealth programs that issue a prescription and check back at month 3 produce real-world TBWL meaningfully below trial means because adherence crashes.
The insurance coverage lever is enormous
KFF’s 2024 employer-survey data showed roughly 18% of large employers covered GLP-1s for weight loss; that figure was 34% by Q4 2025. If your plan is in the covered bracket, the in-person path with manufacturer savings-card stacking ($25–$50/month) produces a cost-per-pound below $20 — unreachable by any cash telehealth path. Patients often do not know whether their plan covers AOMs; the correct first move is to check the formulary for Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide for weight management), not Ozempic or Mounjaro which are T2D-only indications and covered differently. See the insurance coverage checker. If you are covered, the in-person path is a landslide; if you are not, the telehealth path is usually cheaper in year one.
Running the math the right way
The calculator defaults show $299 telehealth bundle vs $60 clinic visit × 4 visits/yr + $499/month drug via LillyDirect. Telehealth annual = $3,588. In-person annual = $240 visits + $5,988 drug = $6,228. Telehealth wins by ~$2,640. But swap the $499 drug for a $50 insurance copay and the comparison inverts entirely: in-person annual = $240 + $600 = $840, saving ~$2,748 vs telehealth. The answer depends entirely on your drug cost path.
FAQ
Which telehealth programs prescribe branded GLP-1s vs compounded?
Sequence (now WW Clinic), Found, and Calibrate generally work within your insurance for branded Wegovy/Zepbound and include care management. Hims, Ro, Henry, Mochi primarily sell compounded semaglutide and tirzepatide from 503A pharmacies, with rising brand referral options. Verify when you sign up.
Can I use my HSA or FSA with a telehealth subscription?
Yes — the subscription fee and the prescription are both eligible medical expenses when tied to a licensed clinician’s prescription for an eligible condition. Save receipts with the clinical note. See the HSA/FSA calculator.
What if my telehealth provider stops compounding GLP-1s?
After the FDA declared the semaglutide and tirzepatide shortages resolved, many telehealth platforms pivoted to LillyDirect or NovoCare referral. Ask about transition plans when signing up — a program with a clear pathway is lower risk than one that depends entirely on ongoing compounding.
Does telehealth hurt my chances of getting insurance coverage later?
Not directly, but insurers often want a documented chronic-disease-management history before approving PAs. If you start on telehealth-compounded and later try to get Wegovy approved through insurance, bring labs and weight trajectory data from the telehealth platform to your PCP. See the prior auth guide.
Do I need an endocrinologist or will a PCP do?
A good PCP can manage uncomplicated GLP-1 therapy for obesity. Endocrinology is warranted for type 2 diabetes, thyroid history, or patients on complex diabetes regimens. Obesity-medicine certified (ABOM) physicians specifically train in this space and are often better than a generalist for comorbid-patient care.
Is compounded semaglutide or tirzepatide the same as the branded drug?
Pharmacologically, the active ingredient is the same peptide. Clinically, the finished product differs on purity, concentration accuracy, excipients, and sterility assurance — all of which depend on the compounding pharmacy’s quality system, not on the peptide itself. 503A pharmacies serve individual prescriptions; 503B outsourcing facilities operate under cGMP and FDA inspection. Since the FDA declared the semaglutide and tirzepatide shortages resolved in late 2024 and early 2025, 503A compounding of those specific peptides has faced legal challenges, and several large telehealth platforms have shifted to LillyDirect/NovoCare referrals or to “personalized” formulations (e.g., semaglutide + B12). Read your prescription carefully.
What should a good intake ask about?
Personal/family history of MTC or MEN2; personal history of pancreatitis; active gallbladder disease; diabetic retinopathy; severe gastroparesis; pregnancy or planned pregnancy; eating disorder history; suicidality history; current medications (especially insulin, sulfonylureas, and medications affected by delayed gastric emptying). A program that skips this screening is a red flag regardless of price.